Rxilient provides pharmaceutical CDMO services.
Rxilient has raised $30.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2023.
Rxilient's investors include Legend Capital, Pharmaron.
Rxilient is headquartered in Singapore, Singapore.
Rxilient provides pharmaceutical CDMO services.
Rxilient is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rxilient — Funding & Investors." VCBacked, October 18, 2023, https://www.vcbacked.co/company/rxilient. Accessed September 30, 2026.
VCBacked. (2023). Rxilient — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/rxilient
{{cite web |title=Rxilient — Funding & Investors |url=https://www.vcbacked.co/company/rxilient |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated